Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
Dr. Rolf Schwiete Research Unit for Osteoarthritis, Orthopaedic University Hospital Friedrichsheim, Frankfurt, Germany.
Bone. 2021 Sep;150:115999. doi: 10.1016/j.bone.2021.115999. Epub 2021 May 8.
During skeletal development most bones are first formed as cartilage templates, which are gradually replaced by bone. If later in life those bones break, temporary cartilage structures emerge to bridge the fractured ends, guiding the regenerative process. This bone formation process, known as endochondral ossification (EO), has been widely studied for its potential to reveal factors that might be used to treat patients with large bone defects. The extracellular matrix of cartilage consists of different types of collagens, proteoglycans and a variety of non-collagenous proteins that organise the collagen fibers in complex networks. Thrombospondin-5, also known as cartilage oligomeric matrix protein (TSP-5/COMP) is abundant in cartilage, where it has been described to enhance collagen fibrillogenesis and to interact with a variety of growth factors, matrix proteins and cellular receptors. However, very little is known about the skeletal distribution of its homologue thrombospondin-4 (TSP-4). In our study, we compared the spatiotemporal expression of TSP-5 and TSP-4 during postnatal bone formation and fracture healing. Our results indicate that in both these settings, TSP-5 distributes across all layers of the transient cartilage, while the localisation of TSP-4 is restricted to the population of hypertrophic chondrocytes. Furthermore, in fractured bones we observed TSP-4 sparsely distributed in the periosteum, while TSP-5 was absent. Last, we analysed the chemoattractant effects of the two proteins on endothelial cells and bone marrow stem cells and hypothesised that, of the two thrombospondins, only TSP-4 might promote blood vessel invasion during ossification. We conclude that TSP-4 is a novel factor involved in bone formation. These findings reveal TSP-4 as an attractive candidate to be evaluated for bone tissue engineering purposes.
在骨骼发育过程中,大多数骨骼最初是由软骨模板形成的,这些软骨模板会逐渐被骨骼取代。如果在生命后期这些骨骼发生骨折,临时的软骨结构会出现,以桥接骨折端,引导再生过程。这种骨形成过程,称为软骨内骨化 (EO),因其可能揭示可用于治疗大骨缺损患者的因素而被广泛研究。软骨的细胞外基质由不同类型的胶原、蛋白聚糖和多种非胶原蛋白组成,它们将胶原纤维组织成复杂的网络。血小板反应蛋白-5(也称为软骨寡聚基质蛋白,TSP-5/COMP)在软骨中含量丰富,在软骨中,它被描述为增强胶原纤维形成,并与多种生长因子、基质蛋白和细胞受体相互作用。然而,关于其同源物血小板反应蛋白-4(TSP-4)在骨骼中的分布知之甚少。在我们的研究中,我们比较了 TSP-5 和 TSP-4 在出生后骨形成和骨折愈合过程中的时空表达。我们的结果表明,在这两种情况下,TSP-5 分布在软骨的所有层中,而 TSP-4 的定位仅限于肥大软骨细胞群体。此外,在骨折的骨骼中,我们观察到 TSP-4 稀疏地分布在骨膜中,而 TSP-5 不存在。最后,我们分析了两种蛋白对内皮细胞和骨髓干细胞的趋化作用,并假设在这两种血小板反应蛋白中,只有 TSP-4 可能在骨化过程中促进血管侵袭。我们得出结论,TSP-4 是一种参与骨形成的新因子。这些发现表明 TSP-4 是一种有吸引力的候选物,可用于骨组织工程目的的评估。